Clinical Trials Browser

Terminated × pasireotide × Clear all

NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2 Terminated

6 enrolled 10 charts

Prostatic Neoplasms

NCT04826432 2024-02-08

PASIREOCHIP

Phase 2 Terminated

Peritoneal Neoplasms

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Phase 2 Terminated

68 enrolled 25 charts

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01372618 2017-12-27

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Phase 1/2 Terminated

9 enrolled 3 charts

Carcinoma, Intraductal, Noninfiltrating

NCT00929669 2017-11-28

LAR

Phase 2 Terminated

2 enrolled 3 charts

Pituitary Neoplasms

NCT01617733 2016-11-02

Pasireotide Therapy in Patients With Nelson's Syndrome

Phase 2 Terminated

Nelson Syndrome

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2 Terminated

118 enrolled 11 charts

EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT00813592 2014-06-11

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

Phase 2 Terminated

2 enrolled 6 charts

Meningioma, Neoplasms